Internalisation of the mu opioid receptor from the surface of cells is generally achieved by receptor occupancy with agonist ligands of high efficacy. However, in many situations the potent analgesic morphine fails to promote internalisation effectively and whether there is a direct link between this and the propensity for the sustained use of morphine to result in both tolerance and dependence has been studied intensely. 
Introduction
Opiates and endogenous enkephalin neuropeptides perform their physiological actions by interacting with four different receptor subtypes, namely mu, delta, kappa and nociceptin receptors, belonging to the superfamily of G protein-coupled receptors [1] . G protein-coupled Morphine, and chemical derivates of this alkaloid, are drugs widely known for their potent analgesic properties in clinical practice as well as for their recreational use. In general, these drugs bind preferentially to mu opioid receptors. In fact, the designation "mu" was originated when it was observed that morphine selectively discriminated this receptor from the other opioid receptor subtypes [1] . More recently, the development and phenotypic characterisation of genetically modified animals lacking expression of mu opioid receptors finally confirmed that morphine exerts both its analgesic and antinociceptive actions through this receptor in living organisms [2] . Although morphine is considered one of the most potent analgesic drugs, especially for the treatment of chronic or refractory pain, its use in clinical practice is limited by the occurrence of tolerance and dependence following prolonged treatment [3] .
Tolerance is defined as a diminishment in the effect of a drug such that larger doses are necessary to produce the initial effect(s). This augmentation of the drug dose required for effect facilitates the development of undesired side effects that, in the case of morphine, may include constipation or respiratory depression. Dependence is related to neuronal changes at both the cellular level and in synaptic organisation that generate physical symptoms following withdrawal of the drug [4, 5] . The fact that not all opioid drugs generate the same degree of tolerance and dependence in experimental animals when they are administered chronically at equi-effective analgesic doses led to consideration that different effects must be produced at the molecular and cellular level when these agonists bind to mu receptors.
The development of recombinant cDNA methodology, combined with a wide range of molecular and cell biology techniques, made possible the expression of particular genes of interest in diverse host cells. Such heterologous expression systems have been extremely useful in investigations of events that occur at the cellular level when a GPCR is activated by a specific agonist. Although initially investigations were focussed predominantly on the β 2 -adrenoceptor, many of the effects observed for this GPCR have been corroborated subsequently for other GPCR family members and have provided a series of paradigms that define key molecular process that occur following receptor activation [6] . Essentially these models postulate that the interaction of an agonist-occupied GPCR with a G protein is interrupted by the phosphorylation of the receptor by specific GPCR kinases or GRKs. This defines that the phosphorylated receptor is more prone to recruit and interact with arrestins than the native state of the receptor. As well as binding directly to GPCRs, the arrestins are cytosolic proteins that operate as scaffolding elements in different cell signalling processes and also facilitate the internalisation of GPCRs, as well as other classes of transmembrane receptors, by recruiting proteins involved in the endocytic machinery, such as clathrin and the AP-2 adapter complex, to form finally an endocytic vesicle. The participation of the GTPase dynamin allows the vesicle to be pinched off from the external membrane. The fate of such endosomes, containing the receptor, is non-uniform; in some cases endosomes merge to eventually form lysosomes that degrade proteins within them. By contrast, in other situations, endosomes are recycled to the plasma membrane, where dephosphorylated GPCRs are refreshed to a state able to interact productively yet again with agonist, re-initiating cellular signalling processes [7] . Regardless of the endocytic pathway followed by the endosomes, it can be considered as a general situation that continual stimulation of a receptor by constant exposure to many agonist drugs results in a reduction of the receptor number in the plasma membrane and within the cell. These processes are known collectively as down-regulation.
In pharmacology, the term desensitisation refers to the loss of responsiveness of the assessed system to the continuing presence of a drug. From a molecular point of view, and in the case of GPCRs, this desensitisation takes place initially when the receptor is phosphorylated and, as a result of this and enhanced interaction with an arrestin, interaction with G-protein is interrupted. The desensitisation of a GPCR is designated as homologous or heterologous dependent on the nature of the protein kinase involved in the phosphorylation event(s) and whether the effect is manifest only on the receptor activated by the agonist [6] . Homologous desensitisation generally occurs when the receptor is activated by a specific agonist and a GRK is involved, whereas heterologous desensitisation refers to the participation of other kinases, e.g. Protein Kinase A or Protein Kinase C, that are activated by specific interacellular secondary messengers, not necessarily generated by the same receptor that becomes phosphorylated. In addition, down-regulation of the total cellular content of a receptor following endocytosis can be considered as another, longer term, mechanism of generating desensitisation. Equivalently, the process of recycling receptor-containing endosomes to the plasma membrane, where the receptor can be activated again by agonist, is known as resensitisation. Therefore, the concept of desensitisation in reference to receptor function may be equivalent to tolerance at the physiological level.
Morphine is distinct when compared to many other agonist drugs that bind to and activate the mu opioid receptor because of a noted accentuated capacity to generate tolerance and dependence when used in long-term treatments. The molecular and cellular basis of this particular feature has been the object of many studies during the last decade, which have resulted in a plethora of concepts and hypotheses, and remains a matter of considerable conjecture and debate [8] [9] [10] [11] [12] [13] . In this review we compile information on several of the approaches and studies that have provided some insight in the basis of this characteristic pharmacological event.
The cloning of cDNA encoding for species orthologues of the mu and other opioid receptors in the early 1990s [1] permitted these receptors to be expressed either transiently or stably in heterologous systems, including transformed mammalian cell lines. As noted earlier, such experimental cell models have been extremely useful to complete the pharmacological characterisation, in terms of drug selectivity as well as agonist efficacies and potencies, of each opioid receptor subtype when expressed individually. Furthermore, such experimental models have allowed genetically modified receptors, for example containing a short amino acid sequence as an epitope that is recognised specifically by an antibody, to be expressed and studied. The use of such epitope-tagged receptors has provided means to employ immunocytochemical and biochemical techniques to facilitate the cellular and molecular studies of these GPCRs. Using such approaches, it was initially described that the rat mu opioid receptor, when stably expressed in HEK293 cells, does not internalise upon treatment with morphine, unlike the effects of enkephalin analogues such as [D-Ala 2 , N-MePhe 4 , Glyol 5 ]-enkephalin (DAMGO) [14] . Similarly, it was observed that the alkaloid etorphine and enkephalin peptides promoted rapid endocytosis of the murine mu opioid and delta opioid receptors expressed in HEK293 cells, whereas morphine did not facilitate the internalisation of these opioid receptors, even at concentrations that strongly inhibited adenylyl cyclase activity [15] . These reports were the first to demonstrate that rapid internalisation of the mu opioid receptor is facilitated by agonist activation, as had been described earlier for the β 2 -adrenoceptor. However, occupancy and activation of the mu opioid receptor by certain agonists, such as morphine, was insufficient to trigger the endocytic process. This feature of morphine seems not to be related to its chemical class because other alkaloid opioids such as etorphine and methadone do promote mu opioid receptor internalisation [15] . This agonistdependency of mu opioid receptor internalisation is not a feature limited to heterologous expression systems. Simultaneous studies employing guinea pig myenteric motor neurons reported the first demonstration of rapid and agonist-selective endocytosis in cells that express mu opioid receptors endogenously. As in HEK293 cells, morphine, unlike etorphine, was completely ineffective in inducing mu opioid receptor internalisation [16] . Since these initial investigations, subsequent research on the inability of morphine to initiate internalisation of the mu opioid receptor has been focussed predominantly on the following questions: 1) Is there a correlation between agonist efficacy to activate the mu opioid receptor and capacity to facilitate receptor endocytosis? 2) What are the defining elements of the receptor protein structure that makes it reluctant to internalise in response to morphine? 3) Which proteins of the GPCR signalling machinery participate in mu receptor endocytosis and how might they facilitate endocytosis to morphine? 4) Is there any relationship between the lack of mu receptor internalisation and the development of tolerance and dependence after chronic morphine treatment? These issues will be considered in turn.
Agonist efficacy and mu opioid receptor endocytosis
Mu opioid receptors exert their actions by coupling preferentially to pertussis toxin-sensitive, heterotrimeric G i /G o G proteins. After their dissociation, the Gα and Gβγ protein subunits regulate distinct effector systems, resulting in the inhibition of adenylyl cyclases, inhibition of voltage-gated calcium channels, stimulation of G protein-activated inwardly rectifying potassium channels (GIRKs) and stimulation of phospholipase Cβ (PLCβ) [1] . The initial characterisation of mu opioid receptors expressed in HEK293 cells [14, 15] showed that effective inhibition of forskolin-stimulated adenylyl cyclase activity by morphine was not accompanied by receptor internalisation. These results led to the hypothesis that cell signalling and the endocytosis of mu opioid receptors in response to morphine were two independent processes. Similarly, observations obtained with a mutant of the rat mu opioid receptor, in which much of the intracellular C-terminal tail was truncated prior to stable expression in HEK293 cells [17] Brain tissue from animals treated with effective analgesic doses of etorphine and morphine were analysed by microscopy and specific antibodies against mu opioid receptors. Receptors in neuronal cells from animals treated with etorphine were distributed mainly in intracellular pools, whereas in cells from animals treated with morphine the receptor was not internalised.
In addition, the same authors assessed a range of different opioid drugs used in clinical practise in a cell line stably expressing the mouse mu opioid receptor and examined internalisation and adenylyl cyclase inhibition. They observed that effects on internalisation of individual ligands were not correlated with their potencies for receptor activation [18] .
Another study performed in cultures of rat hippocampal neurons expressing a transfected, modified version of mu opioid receptor tagged at the C-terminus with the fluorescent protein YFP compared the internalisation promoted by three different agonists, DAMGO, methadone and morphine, with their capacity to induce tolerance in blocking inhibitory transmission and inhibiting voltage gated calcium channels [19] . DAMGO and methadone facilitated the internalisation of this receptor construct in cultured neurons, whereas morphine produced internalisation much more slowly, even after over-expressing β-arrestin-2 in the same cells.
By contrast, the three opioid agonists were equi-effective in inducing tolerance, demonstrating that morphine-induced tolerance in this experimental model was not necessarily accompanied by receptor endocytosis. Other investigations performed in AtT20 cells stably expressing the mouse mu opioid receptor compared DAMGO, morphine, methadone and pentazocine in regard of their efficacy to activate G proteins by monitoring inhibition of calcium channel currents and in their production of rapid, homologous desensitisation to inhibit these calcium channels. In addition, these functional parameters were compared with the ability of the agonists to promote receptor internalisation [20] . A similar rank order of these agonists was observed for their relative efficacies to inhibit calcium channel currents and to generate rapid desensitisation. However, the rank order for the same agonists for internalising the receptor was different. In this experimental model, the efficacy of opioids to produce activation of G proteins and rapid desensitisation was distinct from their capacity to internalise mu opioid receptors. Another important result from this study was that morphine, despite not internalising mu opioid receptors, produced rapid homologous desensitisation as assessed via inhibition of calcium channel currents. This disassociation between the capacity of opioid agonists to desensitise and internalise mu opioid receptor has not always been observed, however. Work conducted in rat locus coeruleus neurons and in HEK293 cells stably expressing rat mu opioid receptors resulted in opposite observations and conclusions [21] . Herein, activation of potassium channels was assessed for either peptide or alkaloid opioid agonists. The compounds presented distinct rank-order when comparing the magnitude of hyperpolarisation and the ability to cause homologous desensitisation. Moreover, the capacity of these agonists to cause receptor endocytosis in HEK293 cells correlated with the degree of desensitisation in locus coeruleus, suggesting that these processes might be linked and that agonist efficacy was not a predictor of the capacity of a particular agonist to cause mu opioid receptor desensitisation and/or internalisation. The basis of the discrepancies between these two reports remain unclear but may be due to the differences in the experimental models used, in terms of the functional assay considered (activation of GIRKs versus inhibition of calcium channel currents), the host cell lines (HEK293 versus AtT20 cells) or the mu opioid receptor orthologue studied (rat versus mouse). Further investigations conducted in AtT20 cells expressing a GFP-tagged version of rat mu opioid receptor demonstrated that receptor uncoupling from G proteins is a GRKdependent process and requires the threonine residue at position 180 [22] . Substitution of threonine 180 by alanine, however, did not inhibit receptor internalisation, suggesting that endocytosis was controlled by a non GRK-dependent mechanism in AtT20 cells. There is further evidence supporting the hypothesis that mu opioid receptor rapid desensitisation and internalisation are independent processes. For example, in a study performed in primary cultured neurons from mouse locus coeruleus, where fluorescent peptides were used to assess mu opioid receptor activation, desensitisation and internalisation, it was observed that desensitisation and recovery were not altered after blocking receptor internalisation using concavalin A [23] .
One of the most elegant demonstrations of the lack of association between agonist efficacy and capacity to induce receptor endocytosis is the experiments reported by Whistler and collaborators using a chimeric mutant of the mu opioid receptor [24] . These studies were performed in HEK293 cells stably expressing either the wild type murine mu opioid receptor or a mu-delta opioid receptor chimera. This receptor mutant, described initially by Afify and collaborators [25] , was generated by exchanging the C-terminal tail between mu and delta opioid receptors. Morphine, unlike other alkaloid agonists and enkephalin analogues, failed to promote either mu or delta opioid receptor endocytosis. However, the chimeric form of the mu opioid receptor containing the C-terminus of the delta opioid receptor, whilst conserving the pharmacological profile of morphine in terms of potency and efficacy, demonstrated strong internalisation upon exposure to morphine. After transient expression of GIRK channels in the same cells, different agonists were assessed for stimulation of potassium currents in parallel with internalisation experiments, explored using both immunocytochemistry and a biotinylation protection assay. Morphine and DAMGO were equi-effective in stimulating potassium currents through either mu or mu-delta opioid receptors whereas, as described earlier, morphine failed to internalise mu opioid receptors.
These studies indicate a key role for the receptor C-terminal tail in defining internalisation (see also section 2) but not the relative functional activity of the agonists. Similar internalisation data were generated in cultured neurons transfected with the same chimeric receptor [24] , thus excluding the possibility of artifactual consequences reflecting the use of HEK293 cells. Although it has been suggested that the poor capacity in many settings of morphine to cause internalisation of the mu receptor might simply reflect the partial agonist nature of this ligand, this is clearly too simple a view to sustain further support.
This lack of correlation between agonist activity/efficacy and capacity to promote receptor endocytosis inspired Whistler and colleagues to propose the RAVE hypothesis [24] . RAVE is the acronym for Receptor Activity Versus Endocytosis, and is a ratio that considers for a particular drug agonist efficacy in relation to its capability to induce receptor endocytosis. For instance, if we consider DAMGO and morphine acting at the mu opioid receptor, both agonists display similar efficacy to stimulate signalling processes in many settings. However, the facilitation of receptor endocytosis by DAMGO is much more extensive than morphine.
This defines that the "RAVE index" for DAMGO is lower than for morphine. The same is true for other alkaloid agonists that promote mu receptor internalisation, such as methadone and etorphine. Mu opioid receptors, as many other GPCRs, generally recycle to the plasma membrane after endocytosis [7] , where they will be ready again to be activated by the agonist.
The absence of receptor internalisation after agonist binding might, therefore, be anticipated 11 to cause a deficiency in receptor desensitisation-resensitisation processes and, as a result, aberrant continuous signalling, resulting in extensive and diverse cellular alterations. The development of tolerance and dependence observed for some opioid drugs, such as morphine, following chronic treatment could be the physiological consequence of these cellular alterations. According to this hypothesis, it could be predicted that opioid agonists presenting a high "RAVE index" would generate stronger levels of tolerance and dependence than those with a lower ratio and several recent investigations have attempted to validate this hypothesis in physiological models of opioid analgesia (see section 4).
Key elements of mu opioid receptor structure implicated in endocytosis
As detailed earlier [24] , it appears that the C-terminal tail of the mu receptor is a key component of its primary structure involved in receptor endocytosis. Initial experiments conducted in HEK293 cells described a mutant form of the rat mu receptor lacking most of the intracellular C-terminal tail that displayed constitutive internalisation and recycling [17] .
Splice variation in the C-terminal tail of mu receptors is common, and the range and extent of variation is species dependent [26] [27] [28] . Characterisation in HEK293 cells of two splice isoforms of the rat mu receptor that vary only in the length of the C-terminal tail, indicated that the shorter isoform desensitised at a slower rate and resensitised more rapidly than the longer isoform when inhibition of intracellular levels of cAMP after stimulation with DAMGO was assessed [29] . Receptor internalisation studies also revealed that the shorter isoform endocytosed faster and recycled more rapidly than the longer isoform [29] . Similar studies have been performed with C-terminal splice variants of the mouse mu receptor stably expressed in HEK293 cells [30] . The MOR1 and MOR1C isoforms were phosphorylated, internalised and down-regulated when stimulated with DAMGO but not in response to morphine. By contrast, the MOR1D and MOR1E splice variants showed similar levels of phosphorylation, internalisation and down-regulation in response to both DAMGO and morphine whilst functional assays measuring inhibition of intracellular cAMP accumulation showed the same desensitisation and resensitisation ratio for DAMGO for each of the four variants, whilst MOR1 and MOR1C desensitised more rapidly and did not resensitise after treatment with morphine. Splice variants of the rat mu receptor have been quantified by RT-PCR in different brain areas [26] , and the three most abundant, i.e. MOR1, MOR1A and MOR1B, were expressed in HEK293 cells together with GIRK channels to assess their regulation. Morphine induced rapid desensitisation for each of these three isoforms whereas DAMGO produced a slower rate of desensitisation via MOR1B. Furthermore, overexpression of a dominant negative mutant of GRK2 demonstrated that the rate of desensitisation of MOR1 and MOR1A was independent of the agonist employed, whilst for MOR1B this was not true. Another comprehensive study generated point mutations,
individually or in combination, of 12 Ser/Thr residues to Ala in the C-terminal tail of the rat mu receptor [31] . Three of these residues (Ser 363 , Thr 370 and Ser
375
) were identified as phosphorylation sites and the internalisation of these mutants in response to DAMGO was explored. The Ser 375 Ala substitution displayed a reduced extent of internalisation, whilst the Ser 363 Ala and Thr 370 Ala substitutions showed significant increases in receptor internalisation kinetics. Although all of the above studies were performed in heterologous expression systems, neurons from mice treated intracerebroventricularly with DAMGO and morphine [32] have been examined by microscopy using antibodies reportedly selective for two MOP receptor splice variants (MOR-1 and MOR-1C). The MOR-1 variant internalised in response to DAMGO but not to morphine whereas MOR-1C internalised in response to both ligands.
Regardless of whether receptor desensitisation and internalisation are correlated or independent processes, the C-terminal intracellular domain is considered to be the region of receptor structure essential for these cellular events. This is not surprising as the receptor C-
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terminus is a domain where many amino acids susceptible to be phosphorylated by different protein kinases are located. Particularly for the rat mu receptor, Ser 375 has been described as a key residue homologously phosphorylated after receptor stimulation with either DAMGO or morphine [33] . Interestingly, DAMGO-stimulated receptors dephosphorylated and then resensitised more rapidly, compared to morphine-occupied receptors, which persisted in the plasma membrane in the phosphorylated state for a longer period of time. Moreover, although not absolutely required for some specific receptors [6] , the interaction of phosphorylated
GPCRs with arrestins to initiate the endocytic process often occurs through the receptor Cterminal intracellular domain [34] . Nevertheless, a recent report [35] describes mu receptor variants outwith the C-terminus that display differences in signalling and internalisation. 
The role of other proteins in mu receptor endocytosis in response to opioid agonists
There are many proteins of the cell endocytic machinery involved in the internalisation of GPCRs after their stimulation by an agonist [6] . As noted earlier, following agonist binding, conformational changes in the receptor promote interaction with GRKs. There are seven GRK subtypes, differentiated by their cell type expression as well as their intracellular distribution [36] . Some, such as GRK2 and GRK3, are cytosolic proteins that migrate to the plasma membrane upon GPCR activation. GRK-mediated phosphorylation and subsequent interactions with arrestins abrogates receptor coupling to G proteins and constitutes, at the molecular and cellular level, the desensitisation process of GPCRs [37] . In addition, arrestins trigger endocytosis by recruiting other proteins, such as clathrin and AP-2, which facilitate the formation of clathrin-coated vesicles. Finally, the GTPase dynamin completes the formation of vesicles and hence sequesters receptors inside endosomes [7] .
Initial experiments in HEK293 cells expressing the murine mu receptor demonstrated that internalisation promoted by etorphine and DAMGO was a dynamin-dependent process [38] .
As noted earlier, morphine failed to induce MOP receptor endocytosis. However, following over-expression of a β-arrestin or GRK2 in these cells, morphine promoted rapid endocytosis of mu receptors. In addition, over-expression of β-arrestin facilitated the uncoupling of mu receptors from G proteins in response to morphine. Similar studies using rat mu receptor, Overall, it is reasonable to conclude that mu receptor internalisation is dynamin-dependent and both GRKs and arrestins are cytosolic protein determinants of the endocytic process.
Nevertheless, it is important to note that, in the majority of cases, conclusions have been receptor or the chimeric mu-delta receptor [43] . Interestingly, there can also be differences in effects of morphine on endogenous mu receptors in distinct compartments of the same cell.
In cell bodies of the nucleus accumbens morphine failed to internalise mu receptors, whereas in neuronal processes morphine produced a rapid and prominent effect on the distribution of mu receptor [43] . This may reflect heterogeneous intracellular distribution of other proteins involved in the endocytic process, such as GRKs and arrestins, but further work is required to assess this directly. In a similar study by the same team using primary cultures of rat striatal neurons [44] , morphine induced the redistribution of both endogenous and recombinant mu receptors. Morphine and DAMGO internalised the receptors to the same extent and in both cases these effects were inhibited by the over-expression of a dominant negative mutant of β-arrestin 2. Although endogenous expression levels of β-arrestin1/2, as assessed by immunoblotting, were equivalent in cultured striatal neurons and HEK293 cells, substantial differences were found in GRK2 expression, with GRK2 being expressed at substantially higher levels in striatal neurons than in HEK293 cells.
Regulators of G-protein signalling (RGS) is other family of proteins involved in GPCR
function, including mu opioid receptors. Receptor signalling processes are modulated negatively by RGS proteins as these facilitate the hydrolysis of GTP associated with Gα subunits and therefore interrupt activation of different cellular effectors. RGS9-2 is a brainspecific splice variant of the RGS9 subtype expressed in neural regions associated with nociception and where mu opioid receptors are expressed. RGS9-2 is particularly highly enriched in striatum and, although expressed at substantially lower levels in PAG and spinal cord, is present [45] . In vitro experiments performed with mouse PAG membranes showed that mu opioid receptor could be co-immunoprecipitated with α-subunits of G i/o/z/q/11 proteins, Gβ 1/2 subunits as well as both RGS9-2 and its partner protein Gβ 5 [46] . These interactions were modulated by morphine since 30 minutes and 3 hours after drug administration the coimmunoprecipitation of mu receptor-Gα subunit was reduced up to 50% whilst the interaction Gα-RGS9-2 was conversely increased. Further studies have examined RGS9-2 involvement in mu opioid receptor endocytosis and signalling [47] . Mouse embryonic fibroblasts (MEF) from both wild type and RGS9-2 knock out animals were transiently transfected with mu receptor and receptor internalisation in response to morphine was explored. Receptors by the mu opioid receptor. Overall, these results indicated that RGS9-2 negatively modulates mu opioid receptor signalling and the rate of receptor endocytosis [47] . Some aspects of these studies are surprising as, in general, the internalisation of many GPCRs does not require signal generation or even the expression of G protein. Thus, further work is required to define if the reported effects of RGS9-2 in these studies is due to the regulation of the G protein GTPase cycle or might reflect that many RGS protein also have direct interactions with other signalling proteins, and in some cases, can interact directly with GPCRs. RGS14 is another RGS subtype that has been linked to mu opioid receptor function. Silencing of RGS14 expression in mouse PAG neurons enhanced mu receptor phosphorylation at Ser 375 in response to morphine [48] . Subsequently the receptors were internalised and recycled to the plasma membrane. Additionally, RGS14 prevented GRK-mediated phosphorylation of mu receptors activated by morphine and, consequently receptor endocytosis mediated by β-
There are other proteins, such as phospholipase D2 (PLD2), that are able to modulate the endocytic process by interacting directly with mu receptors [49] . HEK293 cells stably expressing the rat MOR1 mu receptor and human PLD2 showed receptor internalisation accompanied by an increase in PLD2 activity after treatment with DAMGO. On the other hand, morphine failed either to induce PLD2 activation or to produce receptor endocytosis.
However, phorbol ester activation of PLD2 facilitated the internalisation of mu receptor by both DAMGO and morphine. Furthermore, inhibition of PLD2 by 1-butanol or PLD2 dominant-negative mutants prevented agonist-mediated endocytosis of mu receptors, defining the participation of PLD2 in this process.
Not surprisingly, other GPCRs are able to modulate mu opioid receptor endocytosis. The first demonstration of a receptor facilitating mu receptor internalisation reflected a potential role for mu opioid receptor dimerisation or oligomerisation [50] . These authors demonstrated, firstly in HEK293 cells, that the chimeric mu-delta receptor construct previously described predominantly in recycling endocytic vesicles [53] . Another recent report has described the regulation of mu receptor endocytosis and desensitisation by NK1 neurokinin receptors [54] .
Mouse mu opioid and rat neurokinin 1 receptors were transiently expressed in both primary striatal and amygdala neurons and in the neuroblastoma 2A cell line. Each of these systems is unusual because morphine promotes endocytosis of mu receptors expressed alone. Following co-expression of mu and neurokinin 1 receptors, the activation of the neurokinin 1 receptor population with substance P inhibited mu receptor desensitisation and endocytosis. In addition, this heterologous pairing also resulted in a functionally significant attenuation of morphine-induced desensitisation of mu receptor signalling via adenylyl cyclases. Studies involving over-expression of β-arrestin 2-GFP and a neurokinin 1 receptor mutant unable to interact with β-arrestin2 indicated that the negative modulation of mu receptor endocytosis by 21 the neurokinin 1 receptor might be achieved by sequestering arrestins in endosomes and hence limited their availability to interact with the mu receptor [54] .
Endocytosis of mu opioid receptors and development of morphine tolerance and dependence in living animals
Chronic treatment of experimental animals with morphine results in development of tolerance and dependence to this ligand. Morphine tolerance is manifest as the lost of effectiveness in nociception assays during the course of the sustained administration of an initially effective dose of the drug. In addition, chronic exposure to morphine also results in a dependence that is defined by the appearance of physical symptomatology after the abrupt withdrawal of the drug. Although both processes are the result of morphine action and consequently the result of mu opioid receptor activation, the cellular and molecular basis of each event is different. In physiological terms, tolerance may be considered the result of deficient receptor resensitisation at the cellular level, whereas dependence is more related to changes that occur in diverse elements of the cell signalling machinery involved in receptor activation. The mu opioid receptor couples preferentially to Gαo/i Gprotein subunits and these inhibit the activity of adenylyl cyclases and hence reduce intracellular levels of cAMP. It has been noted for many receptors that couple to inhibitory Gαo/i G proteins that persistent receptor stimulation results in a paradoxical enhancement of adenylyl cyclase activity that increases the levels of accumulated cAMP when the action of the inhibitory receptor is terminated [55] . This adenylyl cyclase superactivation or supersensitisation is considered to be an adaptive cellular response to compensate for chronic inhibitory input. Adenylyl cyclase superactivation has been observed routinely after chronic stimulation of a number of GPCRs (for review see [55] ), and in the case of morphine and the mu opioid receptor it is considered as one of the cellular hallmarks of dependence and withdrawal. As mentioned earlier, the replacement of the C-terminal tail of the mu opioid receptor with the C-terminal tail of the delta opioid receptor generates a chimeric receptor that is endocytosed in response to morphine [24] .
Additional studies conducted by the same authors [56] , evaluated the induction of adenylyl cyclase superactivation by mu opioid receptor mutants expressed in HEK293 cells following chronic treatment with morphine. Mutant receptors that internalised in response to morphine generated a lower cAMP superactivation than the wild-type receptor. Conversely, a mutant form of the receptor that failed to induce GRK-mediated phosphorylation, arrestin recruitment or endocytosis in response to methadone resulted in a higher cAMP superactivation than the wild-type receptor following chronic treatment with this drug. Therefore, there appears to be a negative correlation between agonist facilitation of mu opioid receptor endocytosis and the generation of adenylyl cyclase superactivation. Nevertheless, other reports point to opposite conclusions. Studies with the rat mu opioid receptor expressed in HEK293 cells in a inducible manner [57] described that the magnitude of cAMP superactivation was dependent on mu receptor density, regardless the agonist used, and experiments using dynamin dominantnegative mutants indicated that this process was not dependent on receptor internalisation.
Furthermore, the specifics of cell surface location of mu opioid receptors may to be a determinant for adenylyl cyclase superactivation because after long term agonist treatments the mu receptor was reported to be located in lipid rafts. Similarly, experiments conducted in CHO cells stably expressing the human mu opioid receptor compared DAMGO (internalising ligand) with herkinorin (non-internalising ligand) in their ability to produce tolerance, desensitisation and up-regulation of the cAMP system [58] . That both agonists were equivalent in modulating these pharmacological parameters appears to exclude a direct relationship between mu receptor internalisation and the generation of cAMP superactivation.
Overall, there is still considerable debate and controversy as to whether the production of adenylyl cyclase superactivation is a feature that distinguishes mu opioid agonists that are the concept that mu opioid receptor desensitisation was impaired in these animals [64] . This is despite radioligand binding assays showing no difference to wild type littermates in chronically with morphine showed a reduction of DAMGO stimulation, whereas this was not observed in membranes from the β-arrestin 2 KO mice. Other alterations observed in β-arrestin 2 KO mice were attenuation of both respiratory depression and constipation caused by morphine treatment [66] . Unlike the case for β-arrestin 2, phenotypic characterisation of mice lacking individual GRK subtypes has not provided conclusive results in this regard.
Studies conducted with GRK3 KO mice showed no differences in acute antinociceptive responses to either fentanyl or morphine [67] . However, in vivo experiments assessing electrophysiological response in hippocampus indicated that tolerance to fentanyl was blocked by GRK3 deletion. Another recent report describes the characterisation of GRK6 KO mice [68] . Over-expression of GRK6 in HEK293 cells transiently expressing mu opioid receptors facilitated morphine-induced β-arrestin 2 recruitment and mu receptor internalisation, whilst acute morphine treatment of GRK6 KO mice induced greater locomotor activation but less constipation than in wild-type litter mates. Nevertheless, thermal antinociception, analgesic tolerance and physical dependence were not affected by ablation of the GRK6 gene. The important discrepancy found in this study between in vitro and in vivo results confirms the need for caution when interpreting and/or extrapolating observations from heterologous expression systems to physiological models. As mentioned earlier, RGS proteins play an important role in modulating mu opioid receptor signalling and endocytosis.
Characterisation of RGS9 KO mice revealed that these animals displayed enhanced behavioural responses to acute and chronic morphine treatment [45] . These alterations included morphine analgesia with delayed tolerance that was accompanied by exacerbated signs of physical dependence and withdrawal [45] . Similarly, in vivo knock-down of RGS9-2 expression in mice prevents morphine from altering the association between mu opioid receptors and G-proteins as well as the absence of development of tolerance [46] . As such, these authors concluded that the development of morphine tolerance was caused by the stabilisation and retention of mu receptor-activated Gα subunit complexes by RGS9-2.
Further studies have been performed in mice in which levels of RGS4 could be controlled.
Systemic injections of morphine induced comparable antinociceptive effects in wild type and RGS4 KO animals in the tail flick test as well as in the first reaction of the hot-plate test.
Additionally, no difference between mutant and wild type mice was observed for somatic signs of abstinence to opioids [69] . A recent study employed both constitutive RGS4 KO mice, conditional nucleus accumbens-targeted RGS4 KO mice and mice overexpressing RGS4 in the nucleus accumbens [70] . However, results were difficult to interpret in relation to the actions of morphine since it appeared that in nucleus accumbens RGS4 acted as a negative regulator of morphine reward whereas in locus coeruleus RGS4 opposed the development of physical dependence by morphine. Thus, although RGS4 can act as a positive modulator of opiate analgesics such as methadone and fentanyl, it may not affect either morphine analgesia or tolerance.
Conclusions
Although mu opioid receptors comply with general paradigms established for other GPCRs in terms of receptor desensitisation, internalisation and resensitisation, the initiation of these processes is dependent on the identity of the participating agonist. This has been examined most extensively for morphine, not least because of the widespread use of this drug as a remarkably effective analgesic. In contrast to many other opioid alkaloids and enkephalins, morphine is frequently reported to be unable to promoter effective receptor internalisation despite displaying high agonist efficacy in many (but not all) assays. Because receptor internalisation is believed to be required to allow desensitised GPCRs to resensitise, hypotheses have been developed that suggest that the inability of morphine to promote receptor internalisation is causally linked to the development of tolerance to morphine over time and, potentially, to the symptoms of physical dependence. However, in certain cells and tissues, morphine is able to stimulate mu receptor internalisation from the cell surface, either when used alone or in combination with other receptor ligands ( Table 1 ) . 
